About the School
Professor Chris Paraskeva, Head of School of Cellular and Molecular Medicine
The mission of our school is to teach students how to become successful scientists, in an environment where we undertake world class research, focused on turning science into medicine. We strive to ensure direct alignment of our teaching and research expertise, specialising in cancer biology, infection and immunity and regenerative medicine/stem cell biology. This alignment allows us to deliver teaching to our own science undergraduates, to science undergraduates from other schools and to medical and dental students that is informed by cutting-edge research and to establish research programmes that are grounded in the latest expertise in the field.
We pride ourselves on the exceptional abilities of our students and the excellence of our teaching that leads to a consistently high quality of graduate emerging from the programmes. The quality of our teaching is recognised annually in the National Student Survey (NSS). The School had a 94% student satisfaction rate in the 2016 NSS; 98% of the students thought the staff were good at explaining things.
Our school is an ideal place for postgraduate students to learn rigorous scientific method through their training and research in either a MSc or PhD programme. All research students are mentored by experienced supervisors and all research programmes are embedded within one of the three broad research themes, providing a critical mass of scientists working on related topics. The majority of our PhD graduates go on to work in a research related environment.
Our goal; "turning science into medicine..."
Turning science into medicine is our core research mission and to achieve this ambitious aim we undertake the fundamental science needed to progress ideas through to clinical trials or commercial development. The School has a proven track record for clinical translational work with five world leading 4* 'Impact Cases' in the REF2014.
We also aim to exploit our research discoveries through patent protection and by the formation of spin-out companies. Several spin-out companies have already been established to develope immunomodulatory molecules for autoimmune diseases, stem cells for the prevention of osteoarthritis and providing platform technologies for drug efficacy trials in immune diseases.
I hope you will find our web pages interesting.
Chris Paraskeva, Professor of Experimental Oncology and Head of School